CDH5 (Cadherin-5), also known as VE-cadherin or CD144, is a calcium-dependent cell adhesion protein critical for maintaining endothelial cell junctions and vascular integrity. The FITC-conjugated CDH5 antibody is a fluorescently labeled reagent designed for detecting CDH5 in applications such as flow cytometry (FCM), immunohistochemistry (IHC), and immunofluorescence (IF). FITC (fluorescein isothiocyanate) enables visualization under fluorescence microscopy or flow cytometric analysis, making this antibody a vital tool for studying vascular biology and cancer research .
Abbexa Ltd: Rabbit polyclonal antibody (Catalog #CDH5-Ab-FITC), $380/100 µL .
United States Biological: Mouse monoclonal antibody (FITC-conjugated), $847/100 µL .
Cepham Life Sciences: Rabbit polyclonal antibody, >95% purity, optimized for ELISA and FCM .
CDH5 is essential for endothelial cell adhesion and vascular lumen formation. FITC-conjugated CDH5 antibodies have been used to:
Identify CDH5+ endothelial cells in human placenta and tumor tissues .
Study hypoxia-induced CDH5 upregulation in glioblastoma stem-like cells (GSCs), revealing its role in tumor angiogenesis .
A landmark study (PMC ID: PMC3688011) demonstrated:
CDH5 in Glioblastoma: CDH5+ GSCs exhibit enhanced vasculogenic mimicry under hypoxia. Flow cytometry with FITC-conjugated CDH5 antibodies enabled isolation of CDH5+ cells, which formed xenograft tumors in mice .
Prognostic Value: High CDH5 expression correlates with poor survival in glioblastoma patients (HR = 1.8, P < 0.01) .
| Parameter | Result |
|---|---|
| CDH5 mRNA Levels in GBM | 2.8-fold higher vs. normal tissue (P < 0.05) |
| Hypoxia Response | HIF1α/2α bind CDH5 promoter, upregulating expression in GSCs |
| Vasculogenic Mimicry | CDH5 knockdown reduced tube formation by 60% (P < 0.001) |